Related Experiment Videos
Insights
A myocardial infarction occurred in a teen with hemophilia A during factor IX complex treatment. This rare thromboembolic event highlights potential risks even without pre-existing vascular disease.
Area of Science:
- Hematology
- Cardiology
- Pediatrics
Background:
- Hemophilia A is a genetic bleeding disorder characterized by deficiency in factor VIII.
- Inhibitors to factor VIII can complicate treatment, necessitating alternative factor replacement therapies.
- Factor IX complex is a treatment option, but its use carries potential risks.
Observation:
- A 17-year-old male with hemophilia A and high-titer factor VIII inhibitors received large doses of human factor IX complex (Konyne).
- The patient had a history of type 1 diabetes mellitus managed with insulin.
- No evidence of underlying vascular disease was noted prior to the event.
Findings:
- The patient experienced a myocardial infarction (heart attack) on the sixth day of factor IX complex administration.
- Thromboembolic complications are known but rare following factor IX concentrate use, particularly in classic hemophilia patients.
Implications:
- This case suggests that thromboembolic events, such as myocardial infarction, are a rare but possible complication of factor IX complex therapy in hemophilia A patients.
- The occurrence in a young patient without vascular disease underscores the need for careful monitoring during factor replacement therapy.
- Further investigation may be warranted to understand the specific mechanisms leading to such rare complications.
Abstract:
A 17-year-old boy with hemophilia A and strong inhibitors for factor VIII suffered a myocardial infarction on the sixth day of treatment with large amounts of human factor IX complex (Konyne). The patient also had had diabetes for one year, for which he was receiving insulin injections, but there was no evidence of vascular disease. Thromboembolic complications that occur after the administration of factor IX concentrates have been reported in patients with hemophilia B or liver disease, but these complications are extremely rare in patients with classic hemophilia.